VIVUS to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Dec. 3, 2010 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that senior management will present an overview of the company at two investment conferences during the month of December.

The conference presentation schedule is as follows:




Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference


December 8, 2010 at 12:30 p.m. PT


Nikko Hotel, San Francisco, CA


Presenter: Charles Bowden, MD, director of clinical development




2010 Deutsche Bank BioFEST Conference


December 14, 2010 at 4:05 p.m. ET


Four Seasons Hotel, Boston, MA


Presenter: Timothy Morris, chief financial officer



A live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development is QNEXA®, which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

CONTACT:  






VIVUS, Inc.

Investor Relations:

The Trout Group

Timothy E. Morris


Brian Korb

Chief Financial Officer


[email protected]

650-934-5200


646-378-2923



SOURCE VIVUS, Inc.

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”